Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christine Marosi

Showing results (1-10 of 191) with videos related to

Pageof 20
Sort By:
Wiener Medizinische Wochenschrift (1946)|November 15, 2006
Gender aspects of treatment and drug related toxicity in medical oncologyChristine Marosi
CNS Oncology|July 24, 2014
First-line bevacizumab for glioblastoma: what do recent Trail results mean for future treatment?Christine Marosi
Neuro-Oncology Practice|November 18, 2024
Well-intentioned is not always beneficial: Why we should question prescription habitsChristine Marosi
Ebiomedicine|March 1, 2018
Methylation of PD-1 Promoter Gene as New Prognostic Marker for IDH Mutant Low-Grade Glioma?Christine Marosi
Neuro-Oncology|November 8, 2014
Light at the end of the tunnel: towards an effective drug therapy for surgery- and radiation-refractory meningiomaChristine Marosi
Neuro-Oncology|September 13, 2021
Will mastering ferroptosis allow treating refractory meningiomas?Christine Marosi
Wiener Medizinische Wochenschrift (1946)|September 1, 2006
Chemotherapy for malignant gliomasChristine Marosi
Memo|March 10, 2021
Elderly patients with cancerChristine Marosi
Handbook of Clinical Neurology|January 11, 2012
Complications of chemotherapy in neuro-oncologyChristine Marosi
CNS Oncology|July 24, 2014
Conference scene: Neuro-oncology insights from European Society of Medical Oncology 2012Christine Marosi
Pageof 20

Showing results (1-10 of 191) with videos related to

Sort By:
Pageof 20
Wiener Medizinische Wochenschrift (1946)|November 15, 2006
Gender aspects of treatment and drug related toxicity in medical oncologyChristine Marosi
CNS Oncology|July 24, 2014
First-line bevacizumab for glioblastoma: what do recent Trail results mean for future treatment?Christine Marosi
Neuro-Oncology Practice|November 18, 2024
Well-intentioned is not always beneficial: Why we should question prescription habitsChristine Marosi
Ebiomedicine|March 1, 2018
Methylation of PD-1 Promoter Gene as New Prognostic Marker for IDH Mutant Low-Grade Glioma?Christine Marosi
Neuro-Oncology|November 8, 2014
Light at the end of the tunnel: towards an effective drug therapy for surgery- and radiation-refractory meningiomaChristine Marosi
Neuro-Oncology|September 13, 2021
Will mastering ferroptosis allow treating refractory meningiomas?Christine Marosi
Wiener Medizinische Wochenschrift (1946)|September 1, 2006
Chemotherapy for malignant gliomasChristine Marosi
Memo|March 10, 2021
Elderly patients with cancerChristine Marosi
Handbook of Clinical Neurology|January 11, 2012
Complications of chemotherapy in neuro-oncologyChristine Marosi
CNS Oncology|July 24, 2014
Conference scene: Neuro-oncology insights from European Society of Medical Oncology 2012Christine Marosi
Pageof 20